

# Nadia Mores

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4405226/publications.pdf>

Version: 2024-02-01

53  
papers

1,960  
citations

218677

26  
h-index

243625

44  
g-index

53  
all docs

53  
docs citations

53  
times ranked

2623  
citing authors

#	ARTICLE	IF	CITATIONS
1	Detection and characterisation of extracellular vesicles in exhaled breath condensate and sputum of COPD and severe asthma patients. <i>European Respiratory Journal</i> , 2021, 58, 2003024.	6.7	8
2	NMR-Based Metabolomics for the Assessment of Inhaled Pharmacotherapy in Chronic Obstructive Pulmonary Disease Patients. <i>Journal of Proteome Research</i> , 2020, 19, 64-74.	3.7	14
3	Development of a Sensing Array for Human Breath Analysis Based on SWCNT Layers Functionalized with Semiconductor Organic Molecules. <i>Advanced Healthcare Materials</i> , 2020, 9, e2000377.	7.6	44
4	The discovery and development of acclidinium bromide for the treatment of chronic obstructive pulmonary disease. <i>Expert Opinion on Drug Discovery</i> , 2018, 13, 563-577.	5.0	2
5	Single-inhaler triple therapy utilizing the once-daily combination of fluticasone furoate, umeclidinium and vilanterol in the management of COPD: the current evidence base and future prospects. <i>Therapeutic Advances in Respiratory Disease</i> , 2018, 12, 175346661876077.	2.6	12
6	Favorable Vascular Actions of Angiotensin-(1 $\alpha$ 7) in Human Obesity. <i>Hypertension</i> , 2018, 71, 185-191.	2.7	40
7	Breathomics for Assessing the Effects of Treatment and Withdrawal With Inhaled Beclomethasone/Formoterol in Patients With COPD. <i>Frontiers in Pharmacology</i> , 2018, 9, 258.	3.5	25
8	Metabolomic Analysis by Nuclear Magnetic Resonance Spectroscopy as a New Approach to Understanding Inflammation and Monitoring of Pharmacological Therapy in Children and Young Adults With Cystic Fibrosis. <i>Frontiers in Pharmacology</i> , 2018, 9, 595.	3.5	14
9	Dupilumab for the treatment of asthma. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 357-366.	4.1	47
10	Vascular Effects of Obestatin in Lean and Obese Subjects. <i>Diabetes</i> , 2017, 66, 1214-1221.	0.6	7
11	Beneficial Effects of Apelin on Vascular Function in Patients With Central Obesity. <i>Hypertension</i> , 2017, 69, 942-949.	2.7	23
12	Investigational prostaglandin D2receptor antagonists for airway inflammation. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 639-652.	4.1	21
13	Henoch-SchÅ¶nlein purpura and drug and vaccine use in childhood: a case-control study. <i>Italian Journal of Pediatrics</i> , 2016, 42, 60.	2.6	29
14	Triple inhaled therapy for chronic obstructive pulmonary disease. <i>Drug Discovery Today</i> , 2016, 21, 1820-1827.	6.4	30
15	Vasodilator responses and endothelin-dependent vasoconstriction in metabolically healthy obesity and the metabolic syndrome. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2015, 309, E787-E792.	3.5	49
16	Phenylephrine eye drops in pediatric patients undergoing ophthalmic surgery: incidence, presentation, and management of complications during general anesthesia. <i>Paediatric Anaesthesia</i> , 2014, 24, 400-405.	1.1	27
17	Liquid chromatography-mass spectrometry measurement of leukotrienes in asthma and other respiratory diseases. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2014, 964, 12-25.	2.3	34
18	Vaccine effectiveness against severe laboratory-confirmed influenza in children: Results of two consecutive seasons in Italy. <i>Vaccine</i> , 2014, 32, 4466-4470.	3.8	17

#	ARTICLE	IF	CITATIONS
19	Within-day and between-day repeatability of measurements with an electronic nose in patients with COPD. <i>Journal of Breath Research</i> , 2013, 7, 017103.	3.0	75
20	Leptin Stimulates Both Endothelin-1 and Nitric Oxide Activity in Lean Subjects But Not in Patients With Obesity-Related Metabolic Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 1235-1241.	3.6	57
21	The Electronic Nose in Respiratory Medicine. <i>Respiration</i> , 2013, 85, 72-84.	2.6	151
22	Effects of GLP-1 on Forearm Vasodilator Function and Glucose Disposal During Hyperinsulinemia in the Metabolic Syndrome. <i>Diabetes Care</i> , 2013, 36, 683-689.	8.6	50
23	Stevens-Johnson Syndrome Associated with Drugs and Vaccines in Children: A Case-Control Study. <i>PLoS ONE</i> , 2013, 8, e68231.	2.5	29
24	Rho-kinase inhibition improves vasodilator responsiveness during hyperinsulinemia in the metabolic syndrome. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2012, 303, E806-E811.	3.5	13
25	Further considerations on adverse reactions to radiopharmaceuticals. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 1360-1362.	6.4	12
26	Coexistence of functional angiotensin II type 2 receptors mediating both vasoconstriction and vasodilation in humans. <i>Journal of Hypertension</i> , 2011, 29, 1743-1748.	0.5	15
27	Generalized impairment of vasodilator reactivity during hyperinsulinemia in patients with obesity-related metabolic syndrome. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2010, 299, E947-E952.	3.5	53
28	Heme oxygenase-derived carbon monoxide modulates gonadotropin-releasing hormone release in immortalized hypothalamic neurons. <i>Neuroscience Letters</i> , 2010, 471, 175-178.	2.1	15
29	Chrelin Restores the Endothelin 1/Nitric Oxide Balance in Patients With Obesity-Related Metabolic Syndrome. <i>Hypertension</i> , 2009, 54, 995-1000.	2.7	85
30	Improved endothelial function after endothelin receptor blockade in patients with systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2009, 60, 1840-1844.	6.7	16
31	Tumor Necrosis Factor- $\alpha$ Antagonism Improves Endothelial Dysfunction in Patients With Crohn's Disease. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 83, 70-76.	4.7	66
32	Heme oxygenase expression and activity in immortalized hypothalamic neurons GT1 $\alpha$ . <i>Neuroscience Letters</i> , 2008, 444, 106-108.	2.1	2
33	Tumor Necrosis Factor- $\alpha$ Antagonism Improves Vasodilation During Hyperinsulinemia in Metabolic Syndrome. <i>Diabetes Care</i> , 2008, 31, 1439-1441.	8.6	52
34	Converse Regulatory Functions of Estrogen Receptor- $\alpha$ and - $\beta$ Subtypes Expressed in Hypothalamic Gonadotropin-Releasing Hormone Neurons. <i>Molecular Endocrinology</i> , 2008, 22, 2250-2259.	3.7	60
35	Expression of a Functional G Protein-Coupled Receptor 54-Kisspeptin Autoregulatory System in Hypothalamic Gonadotropin-Releasing Hormone Neurons. <i>Molecular Endocrinology</i> , 2007, 21, 3062-3070.	3.7	62
36	Intravascular tumor necrosis factor $\alpha$ blockade reverses endothelial dysfunction in rheumatoid arthritis. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 80, 275-281.	4.7	52

#	ARTICLE	IF	CITATIONS
37	Serotonin (5-HT) Receptor Subtypes Mediate Specific Modes of 5-HT-Induced Signaling and Regulation of Neurosecretion in Gonadotropin-Releasing Hormone Neurons. <i>Molecular Endocrinology</i> , 2006, 20, 125-135.	3.7	55
38	Essential Role of G Protein-gated Inwardly Rectifying Potassium Channels in Gonadotropin-induced Regulation of GnRH Neuronal Firing and Pulsatile Neurosecretion. <i>Journal of Biological Chemistry</i> , 2006, 281, 25231-25240.	3.4	16
39	Interleukin-18 displays effects opposite to those of interleukin-1 in the regulation of neuroendocrine stress axis. <i>Journal of Neuroimmunology</i> , 2005, 160, 61-67.	2.3	23
40	Plasma levels of cell adhesion molecules during hyperinsulinemia and modulation of vasoactive mediators. <i>Vascular Medicine</i> , 2004, 9, 185-188.	1.5	2
41	An agonist-induced switch in G protein coupling of the gonadotropin-releasing hormone receptor regulates pulsatile neuropeptide secretion. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 2969-2974.	7.1	136
42	Regulation of Ca <sup>2+</sup> -Sensitive Adenylyl Cyclase in Gonadotropin-Releasing Hormone Neurons. <i>Molecular Endocrinology</i> , 2001, 15, 429-440.	3.7	39
43	Regulation of Ca <sup>2+</sup> -Sensitive Adenylyl Cyclase in Gonadotropin-Releasing Hormone Neurons. <i>Molecular Endocrinology</i> , 2001, 15, 429-440.	3.7	11
44	Local Regulation of Gonadotroph Function by Pituitary Gonadotropin-Releasing Hormone. <i>Endocrinology</i> , 2000, 141, 1187-1195.	2.8	14
45	Autocrine Regulation of Gonadotropin-Releasing Hormone Secretion in Cultured Hypothalamic Neurons. <i>Endocrinology</i> , 1999, 140, 1423-1431.	2.8	101
46	Mediation of Cyclic AMP Signaling by the First Intracellular Loop of the Gonadotropin-releasing Hormone Receptor. <i>Journal of Biological Chemistry</i> , 1998, 273, 25581-25586.	3.4	85
47	Muscarinic Regulation of Intracellular Signaling and Neurosecretion in Gonadotropin-Releasing Hormone Neurons. <i>Endocrinology</i> , 1998, 139, 4037-4043.	2.8	71
48	Platelet $\beta_2$ -adrenergic receptors in hypercholesterolemia: Relationship between binding studies and epinephrine-induced platelet aggregation. <i>Clinical Pharmacology and Therapeutics</i> , 1997, 61, 684-691.	4.7	28
49	Presynaptic A <sub>2</sub> -adrenoceptors and neuropeptide Y Y <sub>2</sub> receptors inhibit [ <sup>3</sup> H]noradrenaline release from rat hypothalamic synaptosomes via different mechanisms. <i>Neuroscience Letters</i> , 1995, 188, 9-12.	2.1	22
50	Effects of benazepril on stress testing blood pressure in essential hypertension. <i>American Journal of Cardiology</i> , 1994, 73, 368-373.	1.6	8
51	Region-specific inhibition of potassium-evoked [ <sup>3</sup> H]noradrenaline release from rat brain synaptosomes by neuropeptide Y-(13-36). Involvement of NPY receptors of the Y <sub>2</sub> type. <i>European Journal of Pharmacology</i> , 1993, 230, 231-234.	3.5	37
52	Effect of sustained-release verapamil therapy on the blood pressure at rest and on the pressor response to isometric exertion in hypertensive patients. <i>European Journal of Clinical Pharmacology</i> , 1988, 34, 549-553.	1.9	3
53	Twenty-four-hour blood pressure monitoring after a single dose of sustained-release verapamil. <i>Cardiovascular Drugs and Therapy</i> , 1988, 2, 533-537.	2.6	1